Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Brief description of study
The purpose of this phase I study is to evaluate the safety and tolerability of MK-3475 (Pembrolizumab), a PD-1/PD-L1 blocking agent in patients with HIV using effective antiretroviral therapy with relapsed (has come back after being treated)/refractor (has not gone away with previous treatment) or disseminated AIDS-defining or non-AIDS defining malignancy. This study will gain preliminary insight into the clinical benefits of the investigational drug across a variety of tumors.
Clinical Study Identifier: s16-01365
ClinicalTrials.gov Identifier: NCT02595866
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
